Literature DB >> 14967980

Disseminating effective behavioral interventions for HIV prevention: a cost analysis of a risk-reduction intervention for drug users.

Nicole D Trentacoste1, David R Holtgrave, Charles Collins, Abu Abdul-Quader.   

Abstract

Economic evaluations of researched HIV-prevention interventions assist service providers in decision making and can help disseminate effective interventions into practice. The study described in this article presents a cost analysis of an intervention that was effective in a research setting. This article also provides threshold analyses that set performance standards to determine if an intervention is cost-effective or cost-saving. From a service provider's perspective, the cost for this intervention is estimated at 50306.40 US dollars for one year (for 150 clients). The base-case, cost per client of this intervention is estimated at 335.38 US dollars. Threshold analyses revealed that in order for Safety Point to be considered cost-saving, it should avert at least 0.411 HIV infections per 150 clients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967980     DOI: 10.1097/00124784-200403000-00007

Source DB:  PubMed          Journal:  J Public Health Manag Pract        ISSN: 1078-4659


  3 in total

1.  Cost analyses of peer health worker and mHealth support interventions for improving AIDS care in Rakai, Uganda.

Authors:  Larry W Chang; Joseph Kagaayi; Gertrude Nakigozi; David Serwada; Thomas C Quinn; Ronald H Gray; Robert C Bollinger; Steven J Reynolds; David Holtgrave
Journal:  AIDS Care       Date:  2012-09-13

2.  Determining the Cost-Savings Threshold for HIV Adherence Intervention Studies for Persons with Serious Mental Illness and HIV.

Authors:  Evan S Wu; Aileen Rothbard; David R Holtgrave; Michael B Blank
Journal:  Community Ment Health J       Date:  2014-12-23

3.  Costs of HIV prevention among out-of-treatment drug-using women: results of a randomized controlled trial.

Authors:  Jennifer Prah Ruger; Arbi Ben Abdallah; Linda Cottler
Journal:  Public Health Rep       Date:  2010 Jan-Feb       Impact factor: 2.792

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.